CV

Azita Azarkeivan MD
Degree / Qualification: Professor ; Pediatric Hematology Oncology
Institution: Iranian Blood Transfusion Organization (IBTO) – High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic,
Tehran, Iran.

Moble : 0098-09121490645

E-mail: azazarkeivan@yahoo.com
azazarkeivan@gmail.com

IBTO Address: IBTO bldg. Hemmat Exp.Way ,
Next to Milad Tower
Po Box 14665-1157

Tel: 0098-21-88601501-30
Fax: 0098-21-22250564

Degree - Coarse of study - Name of Institution- Country Date of attendance

1- General physician - Medicin - Shiraz Medical University - Iran -1983-1990

2- Peditric speciality - Medicin - Tehran Medical University - Iran -1992-1995

3- Hematology Oncology Subspeciality- Medicin - Iran Medical University - Iran - 1999-2001

4- Post Doctrate Fellowship- Medicin- Sick children Hospital & Toronto Transfusion Service- Canada-2002-2003

Educational degree	Coarse of study	Name of Institution	Country	Date of attendance
General physician	Medicin	Shiraz Medical University	Iran	1990
Peditric speciality	Medicin	Tehran Medical University	Iran	1995
Hematology Oncology Subspeciality	Medicin	Iran Medical University Obtaining the first national rank in Superspecialized board exams	Iran	2001
Post Doctrate Fellowship	Hematology & Transfusion Medicine	Sick children Hospital & Toronto Transfusion Service	Canada . Toronto	2003

Papers:

1. **Expression of the FAM132B Gene in Iranian Patients with Beta-Thalassemia**
2. F Sarem, **A Azarkeivan**, A Mardani ,M.Shahabi… **International Journal of Hematology-Oncology and Stem Cell Research** Vol 19 No 4 - 2025 ijhoscr.tums.ac.ir

3. **Clinical and Biochemical Heterogeneity in Hemoglobin H Disease: A Comprehensive Analysis of α-Globin Mutations and Transfusion Requirements**
    a. Saniei E, H. Issa AH, **Azarkeivan A**, Abolghasemi H, Karimipoor M. Iran J Blood Cancer. 2025 June 30;17(2): 1-12.

4. **Pyruvate Kinase Deficiency: An Underdiagnosed Cause of Severe Hemolytic Anemia in Iranian Population: Insights From Whole Exome Sequencing of Four Families and Screening of a Population-Specific Database**
5. M. Rafat, Y. Bouraqi, J. Mehrabi Sisakht, A. Azarkeivan, H. Najmabadi, M. Neishabury International Journal of laboratory hematology sep.2025 https://doi.org/10.1111/ijlh.70003

6. **Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study**
7. M. Faranoush, P. Faranoush. I. Heydari, MR Foroughi, **A.Azarkeivan** ,Al.Parsai Kia, N. Sadighnia ,A. Elahinia, A. Zandi, MR Rezvany, N. Hashemi-Madani, A. Ziaee, R. Nekouian, F. Rohani.Health Sci. Rep.;6 October 2023.. wileyonlinelibrary.com/journal https://doi.org/10.1002/hsr2.1624

8. **The Effects of Glutathione Monoethyl Ester on Different Biochemical, Oxidant, and Antioxidant Levels During Storage in Leukoreduced Red Blood Cells**B. Ghezelbash , MR Deyhim , **A. Azarkeivan** , AA. Pourfathollah , N. EskandariAdvanced Biomedical Research 2024| Published by Wolters Kluwer – Medknow

9. **Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies** S. Mohsenian ,O.Seidizadeh,R. Palla, M. Jazebi, A. Azarkeivan,S. Moazezi,MR.Baghaipour,M.Menegatti, F. Peyvandi Haemophilia. 2023;29:827–835

10. **Major histocompatibility complex (MHC) antigens polymorphism and alloimmunization study in thalassemia patients with febrile non-hemolytic transfusion reaction (FNHTR)**
M. Dadashi , MR Ostadali , S. Mohammadi , **A. Azarkeivan** , M. Zadsar **Transfu sion Clinique et Biologique** Volume 30, Issue 2, May 2023, Pages 205-211 Elsevier

11. **Acute and Chronic Effects of Interval Aerobic Exercise on Hepcidin, Ferritin, and Liver Enzymes in Adolescents With Beta-Thalassemia Major**M. Mohabbat ,AH.Barati, A. Azarkeivan, E. Eghbali, H. Arazi Pediatric Exercise Science Volume 37 Issue 3 sep 2024

12. **Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models**E. Bakhshi , R. Ali Akbari Khoei , **A. Azarkeivan** , M. Kooshesh , A. Biglarian Med J Islam Repub Iran. 2017 Dec 17;31:97. doi: 10.14196/mjiri.31.97

13. **Development of Thalassemia Medication Questionnaire (TMQ): an instrument for Measuring Major Thalassemia patients' knowledge and practice regarding their Medications** **A.Azarkeivan,**G.Mohammadnezhad, H. Esmaily J Pharm Care 2022; 10(4): 223-228.

14. **Iron Load Evaluation of Adrenal Glands and Kidneys by using MRI T2* In Iranian Thalassemia Patients.**Shirkavand, A; Razaghi, Z; Akhlaghpoor, Sh; **Azarkeivan, A**; Karimi, M Reviews in Clinical Medicine, 2023, Vol 10, Issue 4, p50

15. **Awareness and practical evaluation of correct use of iron chelators; a study to track the ambiguities of thalassemia patients on their medications in Iran** M. Mousavi, Gh. Mohammadnezhad, F. Yaghmaei, **A. Azarkeivan**, H. Esmaily BMC Research June 2024 Volume 17 article No 163

16. **The Spectrum of *HBB* Mutations among 2315 Beta Thalassemia Patients of a Reference Clinic in Tehran-Iran**N. Bazazzadegan,SS Abedini,**A. Azarkeivan**,S. Banihashemi,N. Nikzat ,**Hemoglobin international journal for hemoglobin research .**Volume 47,2023 Issue 4

17. **Epidemiologic Study of COVID-19 in Iranian Beta-Thalassemia Patients According to Disease Severity**Shirkavand , A.Azarkeivan, M. Akhavan Tavakkoli , M. Maghsoudlou, A. Arab

Khazaeli ,M. Amin Arch Clin Infect Dis. 2023 August; 18(4): https://doi.org/10.5812/archcid-132565.

18. **Genetic Diagnosis of Pyruvate Kinase Deficiency in Undiagnosed Iranian Patients with Severe Hemolytic Anemia, using Whole Exome Sequencing**J. Sisakht ·, M.Mehri ·, H. Najmabadi ·, A. Azarkeivan ·, M. Neishabury Arch Iran Med 2022 Oct 1;25(10):691–697. doi: 10.34172/aim.2022.108

19. **P604: Diagnostic utility of NGS testing in a highly consanguineous population: Findings from 1400+ Iranian patients with Mendelian disorders**Abolhassani · Z. Fattahi.·, M. Beheshtian , M. Fadaee., R. Vazehan,·F. Ahangari, F. Afroozan , H. Yazdan , B. Bozorgmehr , A. Azarkeivan ,M. Beheshti an, , A. Kariminejad· · H. Najmabadi Genetics in Medicine Volume 2 Supplement 1, 2024 - gimopen.org

20. **A Case Study and a Brief Review on Dermatopathological Drug Reaction in Major Thalassemia.** A.Shirkavand ,F Leila Ataie, A. Azarkeivan, Z. Zahedi, Reviews in Clinical Medicine, 2023, Vol 10, Issue 3, p30

21. **CLINICAL FEATURES AND MOLECULAR BASIS OF THALASSEMIC PATIENTS WITH HOMOZYGOTE FORM OF IVSII-I/ IVSII-I MUTATION AND SYNCHRONIZATION WITH A-GENE MUTATION** A.Goodarzi,F.Rad, O.S Esmaeili, F Forouzeshpour, H Najmabadi, A Azarkeivan - **Experimental Hematology , Volume 111, Supplement, 2022, Page S90**

22. **Simultaneous Hepatitis C Virus Genotyping and Variant Detection in Patients with Thalassemia: A Single-Center Phylogenetic Study** F. Safarnezhad , M H .Karbalaie Niya, F. Zamani, H.Ajdarkosh, M .Khoonsari, AH. Faraji, N. Motamed, M. Nikkhah, M,Ameli, S M, Miri, A, Azarkeivan, M R, Sohrabi, H. Keyvani **Middle East J Dig Dis/ Vol. 14/ No. 1/ January 2022**

23. **Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up.** Safarnezhad Tameshkel F, Karbalaie Niya MH, Khoonsari M, Ajdarkosh H, Faraji AH, Nikkhah M, Motamed N, Azarkeivan A, Gholami A, Sohrabi MR, Keyvani H, Zamani F. **Middle East J Dig Dis. 2021 Jan;13(1):27-34. doi: 10.34172/mejdd.2021.200. Epub 2021 Mar 2. PMID: 34712435; PMCID: PMC8531936.**

24. **Prognostic Value Evaluation of HLA-DRB1*07:01, *10, *12, *13:01 Alleles for Alloimmunization in Transfusion-Dependent Thalassemia.** Mezginejad F, Anani Sarab GR, Atarodi K, Oodi A, Azarkeivan A. **Transfus Apher Sci.**

2021Dec;60(6):103271. doi: 10.1016/j.transci.2021.103271. Epub 2021 Sep 6. PMID:34535395.

25. **Clinical and molecular characterization of Iranian patients with congenital fibrinogen disorders.** Mohsenian S, Seidizadeh O, Mirakhorli M, Jazebi M, Azarkeivan A. **Transfus Apher Sci. 2021 Dec;60(6):103203. doi:10.1016/j.transci.2021.103203. Epub 2021 Jul 1. PMID: 34275736.**

26. **Blood group genotyping in alloimmunized multi- transfused thalassemia patients from Iran.** Sarihi R, Oodi A, Dadkhah Tehrani R, Jalali SF, Mardani F, Azarkeivan A,Gudarzi S, Amirizadeh N. **Mol Genet Genomic Med. 2021 Jul;9(7):e1701. doi: 10.1002/mgg3.1701. Epub 2021 May 8. PMID: 33963817; PMCID: PMC8372074.**

27. **Developing a databank for multiple transfusion patients: Rhantigen and phenotype distribution among 3000 regular blood donors in Iran.** Bakhshandeh Z, Amirizadeh N, Maghsoodlu M, Oodi A, Naghi A, Khazaeli AA,Azarkeivan A. **Transfus Apher Sci. 2021 Jun;60(3):103124. doi: 10.1016/j.transci.2021.103124.Epub 2021 Apr 2. PMID: 33839013.**

28. **Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study.** Karimi M, Haghpanah S, Zarei T, Azarkeivan A, Shirkavand A, Matin S, Tavakoli MA, Zahedi Z, De Sanctis V. **Acta Biomed. 2020 Sep 7;91(3):e2020007. doi: 10.23750/abm.v91i3.10155. PMID:32921705; PMCID: PMC7716961.**

29. **ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors .**Shojaei M, Rezvani H, Azarkeivan A, Poopak B**. . Lab Med. 2021 Mar 15;52(2):158-167. doi: 10.1093/labmed/lmaa052. PMID: 32821940.**

30. **Prevalence and mortality inβ-thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience. Br J Haematol. 2020 Aug;190(3):e137-e140.** Karimi M, Haghpanah S, Azarkeivan A, Zahedi Z, Zarei T, Akhavan Tavakoli M,Bazrafshan A, Shirkavand A, De Sanctis V. doi/10.1111:bjh.16911. Epub 2020 Jun 30. PMID: 32484906; PMCID: PMC7300954.

31. **The First Case of BENTA Disease (B Cell Expansion with NF-κB and T Cell Anergy) from Iran. J Clin Immunol. 2021 Jan 13:1–3.** Neishabury M, Azarkeivan A, Mehri M, Najmabadi H, Cheraghi T. doi: 10.1007/s10875-021-00965-0. Epub ahead of print. PMID: 33442788; PMCID: PMC7806197.

32. **Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience. Mediterr J Hematol Infect Dis. 2021 Jan (1)13;1e2021008** Karimi M, Haghpanah S, Azarkeivan A, Matin S, Safaei A, De Sanctis V. . doi: 10.4084/MJHID.2021.008. PMID: 33489047; PMCID: PMC7813286.

33. **Evaluation of endocrine complications in beta-thalassemia intermedia (β-TI): a cross-sectional multicenter study**. **Endocrine. 2020 Jul;69(1):220-227.** Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Kattamis C, Ladis V, Kattamis A, Kilinc Y, Daar S, Alyaarubi S, Khater D, Wali Y, Elshinawy M, Almadhani A, Yassin M, Soliman AT, Canatan D, Obiedat M, Al-Rimawi H, Mariannis D, Christodoulides C, Christou S, Tzoulis P, Campisi S, Di Maio S, De Sanctis V.
34. doi/10.1007:s12020-019-02159-6. Epub 2019 Dec 18. PMID: 31853840.

35. **Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes**M.Neishabury , M. Mehri , Z. Fattahi , H. Najmabadi**, A. Azarkeivan** Haematologica. 2020 Jan;105(1):e1–e4. doi: 10.3324/haematol.2019.216069

36. **Kidd Blood Group Genotyping for Thalassemia Patient in Iran. Indian J Hematol Blood Transfus2020.Jul;36(3):550-555**
37. Jalali SF, Oodi A, Azarkeivan A, Gudarzi S, Amirizadeh N.. doi: 10.1007/s12288-020-01283-y. Epub 2020 Apr 29. PMID ;32647431:PMCID: PMC7326885.

38. **Fertility and pregnancy in Iranian thalassemia patients: An update on transfusion complications. Transfus Med. 2020 Oct;30(5):352-360.** Takhviji V, Zibara K, Azarkeivan A, Mehrvar N, Mehrvar N, Mezginejad F,Khosravi A.doi/10.1111:tme.12707. Epub 2020 Aug 21. PMID: 32820581.

39. **Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes. Haematologica. 2020 Jan;105(1):e1-e4.** Neishabury M, Mehri M, Fattahi Z, Najmabadi H,

Azarkeivan A. doi: 10.3324/haematol.2019.216069. Epub 2019 May 16. PMID: 31097629; PMCID:PMC6939539.

40. **Hb S (HBB: c.20A>T) and α- and β-Thalassemia Coinheritance in Iranian Patients. Hemoglobin. 2020 Mar;44(2):109-112** Azarkeivan A, Cohan N, Niazkar HR, Azizi A, Rad F.. doi: 10.1080/03630269.2020.1757462. Epub 2020 May 6. PMID32370567:

41. **miR-30a regulates γ-globin expression in erythoid precursors of intermediathalassemia through targeting BCL11A. Mol Biol Rep. 2020 May;47(5):3909-3918.** Gholampour MA, Asadi M, Naderi M, Azarkeivan A, Soleimani M, Atashi A. doi: 10.1007/s11033-020-05483-7. Epub 2020 May 13. PMID: 32406020.

42. **The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial , Complementary Therapies in Medicine, 46, pp. 24-28 2019** Sajadi Hezaveh, Z., Azarkeivan, A., Janani, L., Hosseini, S., Shidfar, F.

43. **The Role of Exercise Stress Echocardiography for Determination of Subclinical Cardiac Involvement in β-Thalassemia Major , Hemoglobin, 43(1), pp. 34-37, 2019** Parsaee, M., Pouraliakbar, H., Azarkeivan, A., Ghadrdoost, B., Behjati, M.

44. Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two- Year Follow -Up , Middle East J Dig Dis/ Vol.13/ No.1/ January 2021 27-34 Safarnezhad F., Karbalaie Niya M H., Khoonsari M., Ajdarkosh H., Faraji A H , Nikkhah M., . Motamed N. , Azarkeivan A., Gholami A. Sohrabi M R. Keyvani H. Zamani F,

45. Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy. BMC Med Genet. 2020 Apr 8;21(1):75. Zarghamian P, Azarkeivan A, Arabkhazaeli A, Mardani A, Shahabi M. doi/10.1186:s12881-020-01011-3. PMID: 32268883; PMCID: PMC7140315

46. **ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors. Lab Med. 2020 Aug 21**:lmaa052 Shojaei M, Rezvani H, Azarkeivan A, Poopak B.. doi: 10.1093/labmed/lmaa052. Epub ahead of print. PMID: 32821940.

47. **Role of left atrial structure and function in the early prediction of cardiac iron overload in transfusion-dependent β-Thalassemia patients Iranian Heart Journal, 21(1), pp. 27-33** Parsaee, M., Khansari, N., Azarkeivan, A., (...), Ghadrdoost, B., Mombeini, H.

48. **Distribution of Red Blood Cell Alloantibodies Among Transfusion-Dependent β-Thalassemia Patients in Different Population of Iran: Effect of Ethnicity. Hemoglobin. 2020 Jan;44(1):31-36.** Sarihi R, Amirizadeh N, Oodi A, Azarkeivan A. Doi .03630269.2019.1709205/10.1080 PMID: 32400249.

49. **The Role of Exercise Stress Echocardiography for Determination of Subclinical Cardiac Involvement in β-Thalassemia Major. Hemoglobin. 2019 Jan;43(1):34-37.** Parsaee M, Pouraliakbar H, Azarkeivan A, Ghadrdoost B, Behjati M. doi.03630269.2019.1572620/10.1080:Epub 2019 May 14. PMID: 31084365.

50. **The effect of quercetin on iron overload and inflammation in β-thalassemia major patients:A double-blind randomized clinical trial. Complement Ther Med. 2019 Oct;46:24-28.** Sajadi Hezaveh Z, Azarkeivan A, Janani L, Hosseini S, Shidfar F. doi: 10.1016/j.ctim.2019.02.017. Epub 2019 Feb 26. PMID: 31519283.]

51. **Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial. J Res Med Sci. 2019 Oct 25;24:91.** Sajadi Hezaveh Z, Azarkeivan A, Janani L, Shidfar F. doi: 10.4103/jrms.JRMS_911_18. PMID: 31741663; PMCID: PMC6856539.

52. **Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. J Pediatr Hematol Oncol. 2020 Jan;42(1):23-26** Karimi M, Haghpanah S, Bahoush G, Ansari S, Azarkeivan A, Shahsavani A, Bazrafshan A, Jangjou A. . doi: /10.1097MPH.0000000000001596. PMID: 31568183.

53. **Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study. Arch Virol. 2020 Oct;165(10):2193-2203.** Safarnezhad Tameshkel F, Karbalaie Niya MH, Zamani F, Motamed N, Ajdarkosh H, Vafaeimanesh J, Khoonsari M, Sohrabi MR, Aten S, Azarkeivan A, Eslami MS,

Perumal D, Maadi M, Ghanbari B, Keyvani H. doi: 10.1007/s00705-020-04728-x. Epub 2020 Jul 8. PMID: .32638116

54. **Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study. Acta Biomed. 2020 Sep 7;91(3):**e2020007 Karimi M, Haghpanah S, Zarei T, Azarkeivan A, Shirkavand A, Matin S, Tavakoli MA, Zahedi Z, De Sanctis V. . doi: /10.23750abm.v91i3.10155. PMID: 32921705; PMCID: PMC7716961.

55. **Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes. Haematologica. 2020 Jan;105(1):e1-e4.** Neishabury M, Mehri M, Fattahi Z, Najmabadi H, Azarkeivan A. doi: 10.3324/haematol.2019.216069. Epub 2019 May 16. PMID: 31097629; PMCID:PMC6939539.

56. **Hb S (HBB: c.20A>T) and α- and β-Thalassemia Coinheritance in Iranian Patients. Hemoglobin. 2020 Mar;44(2):109-112** Azarkeivan A, Cohan N, Niazkar HR, Azizi A, Rad F.. doi: 10.1080/03630269.2020.1757462. Epub 2020 May 6. PMID.32370567:

57. **Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy. BMC Med Genet. 2020 Apr 8;21(1):75.** Zarghamian P, Azarkeivan A, Arabkhazaeli A, Mardani A, Shahabi M. doi/10.1186:s12881-020-01011-3. PMID: 32268883; PMCID: PMC7140315

58. **ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors. Lab Med. 2020 Aug 21**:lmaa052 Shojaei M, Rezvani H, Azarkeivan A, Poopak B.. doi: 10.1093/labmed/lmaa052. Epub ahead of print. PMID: 32821940...

59. **Predicting the Risk of Diabetes in Iranian Patients with β-Thalassemia Major / Intermedia Based on Artificial Neural Network**
    a. F. Yousefian ,T. Banirostam , A. Azarkeivan· Signal Processing and Renewable Energy (SPRE) Vol. 3 No. 4 (2019)

60. **HLA- DRB1*15:03 and HLA-DRB1*11: useful predictive alleles for alloantibody production in thalassemia patients. Transfus Med. 2019 Jun;29(3):179-184**. Darvishi P, Sharifi Z, Azarkeivan A, Akbari A, Pourfathollah AA. doi: /0.1111tme.12531. Epub 2018 Apr 25. PMID: 29691938

61. **Novel mutations in mitochondrial carrier family gene SLC25A38, causing congenital sideroblastic anemia in Iranian families, identified by whole exome sequencing. Blood Cells Mol Dis. 2018 Jul;71:39-44**. Mehri M, Zarin M, Ardalani F, Najmabadi H, Azarkeivan A, Neishabury M. doi: 10.1016/j.bcmd.2018.02.002. Epub 2018Feb 22. PMID: 29499877.

62. **Comparative Evaluation of Biochemical and Hematological Parameters of Pre - Storage Leukoreduction during RBC Storage. Int J Hematol Oncol Stem Cell Res. 2018Jan 1;12(1):35-42.** Ghezelbash B, Azarkeivan A, Pourfathollah AA, Deyhim M, Hajati E, Goodarzi A PMID: 29951176; PMCID: PMC6018247.

63. **Frequency of α-Globin Gene Triplications and Coinheritance with β-Globin Gene Mutations in the Iranian Population. Hemoglobin. 2018 Jul;42(4):252-256** Abedini SS, Forouzesh Pour F, Karimi K, Ghaderi Z, Farashi S, Tavakoli Koudehi A, Javadi Pirouz H, Mobini Nejad SB, Azarkeivan A, Najmabadi H. . doi: .03630269.2018.1526192/10.1080Epub 2018 Nov 19. PMID: 30451045.

64. **The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on hematological factors. Indian J Med Microbiol. 2018 Apr-Jun;36(2):224-229.** Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H Naserifar F, Vafaeimanesh J. doi: /10.4103ijmm.IJMM_18_90. PMID: 30084415.

65. **The correlation between cardiac magnetic resonance T2* and left ventricular global longitudinal strain in people with β-thalassemia. Echocardiography. 2018 Apr;35(4):438-444**. Parsaee M, Akiash N, Azarkeivan A, Alizadeh Sani Z, Amin A, Pazoki M, Samiei N, Jalili MA, Adel MH, Rezaian N. doi: /10.1111echo.13801. Epub 2018 Feb 4. PMID: 29399871.

66. **Economic Burden of Thalassemia Major in Iran, 2015. J Res Health Sci. 2016 Summer;16(3):111-115.** Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, Akbari Sari A, Yaseri M, Ahmadi B, Ghaffari M. PMID: 27840337; PMCID: PMC7191027

67. **Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea. Hemoglobin. 2017 Mar;41(2):110-115** Hojjati MT, Azarkeivan A, Pourfathollah AA, Amirizadeh N. . doi: 10.1080/03630269.2017.1290651. PMID: 28696844.

68. **An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients. Pharmacogenomics. 2017 Jul;18(10):995-967** Maroofi N, Azarkeivan A, Banihashemi S, Mohammadparast S, Aghajanirefah A, Banan M.. doi: 10.2217/pgs-2017-0019. Epub 2017 Jun 22. PMID: .28639471

69. **A Comparison of Hemostatic Changes in Splenectomized and Nonsplenectomized β-Thalassemia Intermedia Patients. J Pediatr Hematol Oncol. 2016 Nov;38(8):636-641** Hashemieh M, Azarkeivan A, Sheibani K. . doi: /10.1097MPH.0000000000000670. PMID: 27606436.

70. **Value of speckle tracking echocardiography for detection of clinically silent left ventricular dysfunction in patients with β-thalassemia. Hematology. 2017 Oct;22(9):554-558**. Parsaee M, Saedi S, Joghataei P, Azarkeivan A, Alizadeh Sani Z. doi:0.1080/10245332.2017.1312206. Epub 2017 Apr 12. PMID.28399703:

71. **Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models. Med J Islam Repub Iran. 2017 Dec 17;31:97.** Bakhshi E, Ali Akbari Khoei R, Azarkeivan A, Kooshesh M, Biglarian A. doi: 10.14196/mjiri.31.97. PMID: 29951398; PMCID: PMC6014765.

72. **Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients. Transfus Med. 2014 Aug;24(4):227-32.** Keshvari M, Hajibeigi B, Azarkeivan A, Keyvani H, Behnava B, Saiedi HosseiniSY, Sharafi H, Alavian SM. doi: 10.1111/tme.12133. PMID: 25124072.

73. **Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res. 2017 Apr .138-133:(2)11;1** Hashemieh M, Radfar M, Azarkeivan A, Hosseini abatabaei SMT, Nikbakht S, M, Sheibani K. PMID: 28875008; PMCID: PMC5575726.

74. **Copy number variations of six and seven α-globin genes in a family with intermedia and major thalassemia phenotypes. Expert Rev Hematol. 2015 Oct;8(5):693-8** Farashi S, Vakili S, Faramarzi Garous N, Ashki M, Imanian H, Azarkeivan A, Najmabadi H. . doi: 10.1586/17474086.2015.1075385. Epub 2015 Aug 6. PMID: .26343893

75. **Mutations on the α2-Globin Gene That May Trigger α(+)-Thalassemia. Hemoglobin. 2015;39(6):398-402** Farashi S, Vakili S, Garous NF, Ashki M, Imanian H, Azarkeivan A, Najmabadi H.. doi: 0.3109/03630269.2015.1075890. Epub 2015 Sep 2. PMID: 26329872.

76. **Characterization of Homozygous Hb Setif (HBA2: c.283G>T) in the Iranian Population. Hemoglobin. 2016;40(1):53-5.** Farashi S, Garous NF, Vakili S, Ashki M, Imanian H, Azarkeivan A, Najmabadi H. doi: 10.3109/03630269.2015.1091357. Epub 2015 Nov 16. PMID: 26574177.

77. **Relation between serum ferritin and liver and heart MRI T2* in beta thalassaemia major patients. East Mediterr Health J. 2013 Aug;19(8):727-32.** Azarkeivan A, Hashemieh M, Akhlaghpoor S, Shirkavand A, Yaseri M, Sheibani K. PMID: 24975358.

78. **T2* Magnetic Resonance Imaging Study of Pancreatic Iron Overload and its Relation With the Diabetic State in Thalassemic Patients. J Pediatr Hematol Oncol. 2017 Jul;39(5):337-340** Hashemieh M, Radfar M, Azarkeivan A, Noghabaei G, Sheibani K. . doi: 10.1097/MPH.0000000000000767. PMID: 28085743.

79. **Evaluation of α-Globin Gene Mutations Among Different Ethnic Groups in Khuzestan Province, Southwest Iran. Hemoglobin. 2016;40(2):113-7** Khosravi A, Jalali-Far M, Saki N, Hosseini H, Galehdari H, Kiani-Ghalesardi O,

Paridar M, Azarkeivan A, Magaji-Hamid K.. doi: 0.3109/03630269.2015.1130720. Epub 2016 Feb .15PMID: 26878087.

80. **Identification of Mutations Causing Aberrant Termination and Deficient Splice Donor Site on the HBA1 Gene. Hemoglobin. 2016;40(1):38-43** Farashi S, Vakili S, Garous NF, Ashki M, Forouzesh Pour F, Zeinali F, Rad F, Imanian H, Azarkeivan A, Najmabadi H. . doi: 10.3109/03630269.2015.1088456. Epub 2015 Nov .4PMID: 26531168.

81. **Interaction of an α-Globin Gene Triplication with β-Globin Gene Mutations in Iranian Patients with β-Thalassemia Intermedia. Hemoglobin. 2015;39(3):201-6** Farashi S, Bayat N, Faramarzi Garous N, Ashki M, Montajabi Niat M, Vakili S, Imanian H, Zeinali S, Najmabadi H, Azarkeivan A. doi: 10.3109/03630269.2015.1027914. Epub 2015 Jun 18. PMID: 26084319.

82. **A Large Cohort Study of Genotype and Phenotype Correlations of Beta-Thalassemia in Iranian Population Int J Hematol Oncol Stem Cell Res. 2015 Oct 1;9(4):198-202**. Maryami F, Azarkeivan A, Fallah MS, Zeinali S. PMID: 26865931;PMCID: PMC4748687.

83. **Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran. Arch Iran Med. 2016 Feb;19(2):96-100**. Azarkeivan A, Hashemieh M, Shirkavand A, Sheibani K. PMID: 26838079.

84. **Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior. Caspian J Intern Med. 2017 Summer;8(3):159-164**. Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. doi: 10.22088/cjim.8.3.159. PMID: 28932366; PMCID: PMC5596185.

85. **Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran. Indian J Hematol Blood Transfus. 2016 Dec;32(4):447-453** Ahmadi MH, Hantuoshzadeh S, Okhovat MA, Nasiri N, Azarkeivan A, Amirizadeh N.. doi: 10.1007/s12288-015-0616-0. Epub 2015 Nov 6. PMID: ;27812255PMCID: PMC5074954.

86. **JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res. 2016 Apr;1 10(2) 70-8.** Ferdowsi S, Ghaffari SH, Amirizadeh N, Azarkeivan A, Atarodi K, Faranoush M, Toogeh G, Shirkoohi R, Vaezi M, Maghsoodlu M, Alimoghaddam K, Ghavamzadeh A, Teimori Naghadeh H. PMID: 27252806; PMCID: PMC4888151.

87. **First Report of a Dominantly Inherited β-Thalassemia Caused by a Novel Elongated β-Globin Chain. Hemoglobin. 2016;40(2):102-7.** Farashi S, Rad F, Shahmohammadi B, Imanian H, Azarkeivan A, Najmabadi H. doi: .03630269.2015.1135445/10.3109Epub 2016 Feb 5. PMID: 26850598.

88. **Point mutations which should not be overlooked in Hb H disease. Expert Rev Hematol. 2016 Jan;9(1):107-13** Farashi S, Bayat N, Vakili S, Faramarzi Garous N, Ashki M, Imanian H,Najmabadi H, Azarkeivan A. . Doi .17474086.2016.1107470/10.1586Epub 2015 Nov 2. PMID: 26523940.

89. **RBC alloimmunization and double alloantibodies in thalassemic patients. Hematology. 2015 May;20(4):223-7.** Azarkeivan A, Ahmadi MH, Zolfaghari S, Shaiegan M, Ferdowsi S, Rezaei N, Lotfi P. doi: 10.1179/1607845414Y.0000000189. Epub 2014 Aug 17. PMID: 25130935.

90. **Hb Dartmouth (HBA2: c.200T>C): An α2-Globin Gene Associated with Hb H Disease in One Homozygous Patient. Hemoglobin.2015; 39 (3) :152-5 .**Farashi S, Faramarzi Garous N, Ashki M, Vakili S, Zeinali F, Imanian H, Azarkeivan A, Najmabadi H. doi: 10.3109/03630269.2015.1027915. Epub 2015 May 15. PMID: .25976777

91. **Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. Int J Lab Hematol. 2015 Oct;37(5):661-7.** Ferdowsi S, Atarodi K, Amirizadeh N, Toogeh G, Azarkeivan A, Shirkoohi R, Faranoush M, Vaezi M, Alimoghaddam K, Ghavamzadeh A, Naghadeh HT, Ghaffari SH. doi: 10.1111/ijlh.12381. Epub 2015May 25. PMID: 26011312.

92. **A 21 Nucleotide Duplication on the α1- and α2-Globin Genes Involves a Variety of Hypochromic Microcytic Anemias, From Mild to Hb H Disease. Hemoglobin. 2015;39(3):196-200**. Farashi S, Faramarzi Garous N, Zeinali F,

Vakili S, Ashki M, Imanian H, Najmabadi H, Azarkeivan A, Tamaddoni A. doi: .03630269.2015.1030757/10.3109Epub 2015 May 15. PMID: 25976776.

93. **Homozygosity for the AATAAA > AATA- - Polyadenylation Site Mutation on the α2-Globin Gene Causing Transfusion-Dependent Hb H Disease in an Iranian Patient: A Case Report. Hemoglobin. 2015;39(5):355-8**. Farashi S, Garous NF, Ashki M, Vakili S, Zeinali F, Imanian H, Azarkeivan A, Giordano PC, Najmabadi H. doi: .03630269.2015.1059850/10.3109Epub 2015 Jul 21. PMID: 26193977.

94. **Characterizing a cohort of α-thalassemia couples collected during screening for hemoglobinopathies: 14 years of an Iranian experience. Hemoglobin. 2014;38(3):153-7** Hafezi-Nejad N, Khosravi M, Bayat N, Kariminejad A, Hadavi V, Oberkanins C,Azarkeivan A, Najmabadi H.. doi: 10.3109/03630269.2014.909365. PMID: 24826790.

95. **Mutation screening of the Krüppel-like factor 1 gene using single-strand conformational polymorphism in a cohort of Iranian β-thalassemia patients. Hemoglobin. 2015;39(1):24-9**. Zaker-Kandjani B, Namdar-Aligoodarzi P, Azarkeivan A, Najmabadi H, Banan M. doi: 10.3109/03630269.2014.991023. Epub 2015 Jan .13PMID: 25583416.

96. **Quality of life in patients with thalassemia major. Iran J Ped Hematol Oncol. .63-57:(2)4;2014** Ansari Sh, Baghersalimi A, Azarkeivan A, Nojomi M, Hassanzadeh Rad A Epub 2014 Apr 20. PMID: 25002926; PMCID: PMC4083201

97. **Erythrocytic phosphatidylserine exposure and hemostatic alterations in β-thalassemia intermediate patients. Hematology. 2014 Dec;19(8):472-6.** Zahedpanah M, Azarkeivan A, Aghaieepour M, Nikogoftar M, Ahmadinegad M, Hajibeigi B, Tabatabaiee MR, Maghsudlu M. doi: 10.1179/1607845413Y.0000000148. Epub 2014 Jan 20. PMID: 24620948.

98. **Utility of the multivariate approach in predicting β-thalassemia intermedia or β-thalassemia major types In Iranian patients. Hemoglobin. 2013;37(5):413-22** Banan M, Bayat H, Namdar-Aligoodarzi P, Azarkeivan A,

Kamali K, Daneshmand P, Zaker-Kandjani B, Najmabadi H. . doi: 10.3109/03630269.2013.805418. Epub 2013Jun 27. PMID: 23805990.

99. **Novel mutations responsible for α-thalassemia in Iranian families. Hemoglobin. 2013;37(2):148-59** Bayat N, Farashi S, Hafezi-Nejad N, Faramarzi N, Ashki M, Vakili S, Imanian H, Khosravi M, Azar-Keivan A, Najmabadi H.. doi: .03630269.2013.763821/10.3109Epub 2013 Feb 12. PMID: 23402770.

100. **Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and risk of osteopenia in β-thalassemia major patients. Hemoglobin. 2013; 37 (6) 564-73** Sahmani M, Gholami A, Azarkeivan A, Darabi M, Ahmadi MH, Sabet MS, Najafipour R. .doi: 10.3109/03630269.2013.814035. Epub 2013 Aug 5. PMID: .23909657

101. **T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Arch Iran Med. 2012 Feb;15(2):91-4** Hashemieh M, Azarkeivan A, Akhlaghpoor S, Shirkavand A, Sheibani K.. PMID: 22292579.

102. **The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin. 2012;36(4):371-80** Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, Bayat N, Khani MH, Neishabury M, Najmabadi H.. doi: 10.3109/03630269.2012.691147. Epub 2012Jun 11. PMID: 22686296.

103. **The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background. Blood Cells Mol Dis. 2013 Aug;51(2):80-4** Neishabury M, Zamani F, Keyhani E, Azarkeivan A, Abedini SS, Eslami MS, Kakroodi ST, Vesiehsari MJ, Najmabadi H.. doi: /10.1016j.bcmd.2013.02.007. Epub 2013 Mar 28. PMID: 23541515.

104. **Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2013 May;98(5):696-704** Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, van

Ijcken W, Philipsen S, Najmabadi H, Grosveld F. . doi: 10.3324/haematol.2012.074492. Epub 2012 Oct 25. PMID: ;23100274PMCID: PMC3640112.

105. **Partial radiofrequency ablation of the spleen in thalassemia. Diagn Interv Radiol. 2012 Jul-Aug;18(4):397-402** Hashemieh M, Akhlaghpoor S, Azarkeivan A, Azizahari A, Shirkavand A, Sheibani K.. doi: 10.4261/1305-3825.DIR.4537-11.1.Epub 2012 Feb 13. PMID: 22328281.

106. **Evaluation of new cases of HCV infection in thalassaemia patients for source of infection. Asian J Transfus Sci. 2011 Jul;5(2):132-5** Azarkeivan A, Nasiritoosi M, Kafiabad SA, Maghsudlu M, Hajibeigi B Hadizadeh M. doi: .6247.83237-0973/10.4103PMID: 21897590; PMCID: PMC3159241.

107. **Genotype-phenotype correlation in Iranian patients with Hb H disease. Hemoglobin. 2011;35(1):40-6** Ebrahimkhani S, Azarkeivan A, Bayat N, Houry-Parvin M, Jalil-Nejad S, Zand S, Golkar Z, Hadavi V, Imanian H, Oberkanins C, Najmabadi H. doi: 10.3109/03630269.2010.546314. PMID: 21250880.

108. **Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis. 2010 Feb;15(2):196-203** .Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P. doi: 10.1007/s10495-009-0417-8. PMID: 19882354.

109. **The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study. Transfusion. 2012 Aug;52(8):1814-8.** Azarkeivan A, Toosi MN, Maghsudlu M, Kafiabad SA, Hajibeigi B, Hadizadeh M .

110. doi: 10.1111/j.1537-2995.2012.03652.x. Epub 2012 Apr 15. PMID: .22500658

111. **Analyzing 5'HS3 and 5'HS4 LCR core regions and NF-E2 in Iranian thalassemia intermedia patients with normal or carrier status for beta-globin mutations. Blood Cells Mol Dis. 2011 Mar 15;46(3):201- 5** Neishabury M, Azarkeivan A, Oberkanins C, Abedini SS, Zamani S, Najmabadi H. . doi: 10.1016/j.bcmd.2010.12.007. Epub 2011 Jan 12. PMID: 21232998.

112. **The modifying effect of Xmn1-HBG2 on thalassemic phenotype is associated with its linked elements in the beta globin locus control region, including the palindromic site at 5'HS4. Blood Cells Mol Dis. 2012 Jan .5-1:(1)48;15** Neishabury M, Zamani S, Azarkeivan A, Abedini SS, Darvish H, Zamani F, Najmabadi H. doi: 10.1016/j.bcmd.2011.10.001. Epub 2011 Oct 28. PMID: 22036762.

113. **Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels? Hematology. 2012 Nov;17(6):367-71** Karimi M, Azarkeivan A, Zareifar S, Cohan N, Bordbar MR, Haghpanah S.. Doi 1024533212/10.1179Z.000000000143. PMID: 23168076.

114. **Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non- comparative study. Daru. 2011;19(3):240-8.** Eshghi P, Farahmandinia Z, Molavi M, Naderi M, Jafroodi M, Hoorfar H, Davari K, Azarkeivan A, Keikhaie B, Ansari S, Arasteh M. PMID: 22615664; PMCID: PMC3232111.

115. **T2* magnetic resonance imaging of the liver in thalassemic patients in Iran. World J Gastroenterol. 2011 Jan 28;17(4):522-5** Zamani F, Razmjou S, Akhlaghpoor S, Eslami SM, Azarkeivan A, Amiri A. . doi: 10.3748/wjg.v17.i4.522. PMID: ;21274383PMCID: PMC3027020.

116. **Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol. 2011 Sep;28(6):479-85.** Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, Shaigan M, Toolabi A, Salahmand M. doi: 10.3109/08880018.2011.568595. PMID: 21854216

117. **Frequency of positive XmnIGgamma polymorphism and coinheritance of common alpha thalassemia mutations do not show statistically significant difference between thalassemia major and intermedia cases with homozygous IVSII-1 mutation. Blood Cells Mol Dis. 2010 Mar- Apr;44(2):95-9.** Neishabury M, Azarkeivan A, Najmabadi H. doi: 10.1016/j.bcmd.2009.10.007. Epub 2009 Nov 4. PMID: .19892574

118. **A report of 8 cases with hemoglobin H disease in an Iranian family.Pediatr Hematol Oncol. 2010 Aug;27(5):405-12**. Azarkeivan A, Neishabury M, Hadavi V, Esteghamat F, Enrahimkhani S, Najmabadi H. doi: 10.3109/08880010903536201.

119. **Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect). Pediatr Hematol Oncol. 2009 Jun;26(4):195-201** Azarkeivan A, Karimi G, Shaiegan M, Maghsudlu M, Tabbaroki A. . doi: 10.1080/08880010902895900. PMID: 19437322

120. **Malignancies in patients with beta-thalassemia major and beta-thalassemia intermedia: a multicenter study in Iran. Pediatr Blood Cancer. 2009 Dec;53(6):1064-7**. Karimi M, Giti R, Haghpanah S, Azarkeivan A, Hoofar H, Eslami M. doi: 10.1002/pbc.22144. PMID: 19533641.

121. **Associates of poor physical and mental health-related quality of life in beta thalassemia- major/intermedia. J Res Med Sci. 2009 Nov;14(6):349-55.** Azarkeivan A, Hajibeigi B, Alavian SM, Lankarani MM, Assari S. PMID: 21772908; PMCID: PMC3129078

122. **Alpha-thalassemia mutations in Khuzestan Province, Southwest Iran. Hemoglobin. 2008;32(6):546-52.** Zandian K, Nateghi J, Keikhaie B, Pedram M, Hafezi-Nejad N, Hadavi V, Oberkanins C, Azarkeivan A, Law HY, Najmabadi H. doi: .03630260802532780/10.1080PMID: 19065332.

123. **Molecular mechanisms underlying thalassemia intermedia in Iran. Genet Test. 2008 Dec;12(4):549-56** Neishabury M, Azarkeivan A, Oberkanins C, Esteghamat F, Amirizadeh N, Najmabadi H.. doi: 10.1089/gte.2008.0018. PMID: 18939939

124. **Pulmonary function test in transfusion-dependent beta-thalassemia patients. Pediatr Hematol Oncol 2008 Sep;25(6):598-606.**Azarkeivan A, Mehrvar A, Pour HS, Mehrvar N, Vosough P. doi: 10.1080/08880010802237294. PMID: 18728979.

125. **Endocrinopathies in patients with transfusion-dependent beta-thalassemia. Pediatr Hematol Oncol. 2008 Apr-May;25(3):187-94** Mehrvar A,

Azarkeivan A, Faranoush M, Mehrvar N, Saberinedjad J, Ghorbani R, Vossough P.. doi: .08880010801938207/10.1080PMID: 18432501.

126. **Elucidating the spectrum of alpha-thalassemia mutations in Iran. Haematologica. 2007 Jul;92(7):992-3**. Hadavi V, Taromchi AH, Malekpour M, Gholami B, Law HY, Almadani N, Afroozan F, Sahebjam F, Pajouh P, Kariminejad R, Kariminejad MH, Azarkeivan A, Jafroodi M, Tamaddoni A, Puehringer H, Oberkanins C, Najmabadi Hdoi: 10.3324/haematol.10658. PMID: 17606454.

127. **Screening of Iranian thalassemic families for the most common deletions of the beta-globin gene cluster. Hemoglobin. 2007;31(4):463-9.** Esteghamat F, Imanian H, Azarkeivan A, Pourfarzad F, Almadani N, Najmabadi H. doi: .03630260701641286/10.1080PMID: 17994380.

128. **Bone mineral density in Iranian adolescents and young adults with beta- thalassemia major. Pediatr Hematol Oncol. 2007 Oct-Nov;24(7):469-79** Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pakbaz Z, Tabatabaie SM, Bouzari N, Pourzahedgilani N, Azarkeivan A, Hashemi SR, Moosavi F, Alebouyeh M, Vosough P, Kimiagar M, Shamshirsaz AA, Moradi M, Habibzadeh MR, Nobakhthaghighi N, Larijani B.. doi: .08880010701533702/10.1080PMID: 17786783.

129. **Pregnancy in patients treated for beta thalassemia major in two centers (Ali Asghar Children's Hospital and Thalassemia Clinic): outcome for mothers and newborn infants. Pediatr Hematol Oncol. 2006 Jan-Feb;23(1):33-7** Ansari S, Azarkeivan A, Tabaroki A. . doi: 10.1080/08880010500313306. Erratum in: Pediatr Hematol Oncol. 2008 Mar;25(2):163. Kivan, Azita Azar [corrected to Azarkeivan, Azita.[PMID: 16326410.

130. **Clinical evaluation of 413 Thalassemic patients The Journal of Tehran Faculty of medicin 2000;3(58): 41-35** Rabbani A, AzarKeivan A, Farhadi Langeroudi M, Korosdari Gh.H

131. **Bone mineral density in 10-20 year old patients with Thalassemia major and its related factors, Tehran, 2001 . Pejouhandeh Quarterly Research Journal 2003;31(8): 5-1** Tabatabaie Far M, Abdollah Shamshirsaz AR, Bakhirnia MR, Kamgar M, Moradi Lakeh M, Aleh Bouyeh M, Moosavi F,

Azarkeivan A, Kimiagar M, Hashemi R, Boozari N, Pourzahed Gilani N, Abdollah Shamshirsaz AH

132. **A case report of Thalassemia with cold agglutinin , Sci J Iran Blood Transfus Org 2005;4(2): 138-135** Azarkeivan A, Sadri A, Ansari Damavandi Sh

133. **Prevalence of sexual maturation rate abnormalities in pateints with beta thalassemia in Iran , Journal of army University of Medical Sciences of the I.R.Iran . Summer 2007 , 5(2): 1233-8** Mehrvar A., Azarkeivan A. , Saberinedjad J. , Mehrvar N., Faranoush M. , Vossough P.

134. **A case of Hemoglobin Lepore combined with beta thalassemia (heterozygote form)** , **Sci J Iran Blood Transfus Org 2007;4(3): 231-6** Azarkeivan A. Najmabadi H. Esteghamat F. ImanianH. Ebrahimkhani S.

135. **Evaluation of hypothyroidism and hypoparathyroidism in Thalassemic Patients referred to the Tehran Adult Thalssemia Clinic, Sci J Iran Blood Transfus Org 2008;5(1): 231-6** Mehrvar A., Azarkeivan A. , Saberinedjad J. , Mehrvar N., Faranoush M. , Vossough P.

136. **Study of Immune Response to Hepatitis B Vaccination in Acute Lymphoblastic Leukemia(ALL) Patients in the Maintenance Phase of Chemotherapy in Ali Asghar Hospital , Journal of Iran University of Medical Sciences 2007;56(14): 173-180** Mehrvar, P. Vosoogh, N. Mehrvar, A. Azarkeivan, Kh. Arjmandi, h. Ansari, H. Nickfarjam

137. **Evaluation of Transfusion Reactions in Thalassemic Patients referred to the Tehran Adult Thalssemia Clinic , The Journal of Zanjan Faculty of Medicine , 2008;1(58): 35-41** Azarkeivan A, Ahmadi MH, Hajibeigy B, Gharebaghian A, Shabeh Pour Z, Maghsoodlu M

138. **Antibody screening & identification by gel method in chronic transfusion patients (thalassemics) , Sci J Iran Blood Transfus Org 2008;5(2): 233-42** Azarkeivan A., Ahmadi M.H., Gharehbaghian A., Zolfaghari S., Nasizadeh S, Maghsudlu M., Toolabi A.M , Lotfy P.

139. **Molecular mechanisms underlying thalassemia intermedia in Iran** , **Genet Test. 2008 Dec;12(4):549-556** Neishaboury M., Azarkeivan A., Oberkanins c., Esteghamat F., Amirizadeh N., Najmabadi H.

140. **α Thalassemia mutation in Khuzestan province , South west Iran , Hemoglobin. 2008;32(6):546-52** Zandian, teghi,Keikhahi,Pedram,Hafezi-nejad, Hadavi, Oberkanins,Azarkeivan,Law, Najmabadi

141. **Cardiac involvement in patients with transfusion dependent thalassemia , Research Journal of Biological Science 4(2):195-199 2009** .Azarkeivan., A.Mehrvar ,M.Faranoush. P.Vossough , N.Mehrvar., R.Ghorbani.,A.Shahmohamadi . , MA.Ehsani , AA.Hedayatiasl

142. Antibody Titration and Immune response of Iranianβ thalassemic patients to Hepatitis B Viruse vaccine (Booster Effect) , Pediatric Hematology and Oncology, 26:195–201, 2009 Azarkeivan A. , Karimi Gh. , Shaigan M. , Maghsoodlu M. ,Tabbaroki A.

143. **Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia , JRMS/ September & October 2009; Vol 14, No 5.** AzarkeivanA. , HajibeigiB., AlavianS.M., LankaraniM., AssariSh.

144. **Malignancies in Patients With b-Thalassemia Major and beta Thalassemia Intermedia: A Multicenter Study in Iran, Pediatr Blood Cancer 2009;53:1064–1067** Mehran Karimi, Rahil Giti, Sezaneh Haghpanah, Azita Azarkeivan,Hamid Hoofar, Masoomeh Eslami,

145. Relationship between HA-1 disparity and acute GVHD after hematopoietic stem cell transplanation , Sci J Iran Blood Transfus Org, 2009; 6(1): 31-40 Shaiegan M., Mohammadi S., Samiee Sh., Ali Moghaddam K., Babaiee Gh.,Ghashghaiee A., Rostami Sh., Khatami F, Azarkeivan A.,Zolfaghari Anaraki S., Ataiee Z., Ghavamzadeh A.

146. **Prevalence of thyroid dysfunction and relevant risk factors among thalassmia patients having referred to Iranian Blood Transfusion Organization Clinical Laboratory of Tehran, Sci J Iran Blood Transfus Org 2009; 6(1): 59-64),** Jalali Farahani F., Zolfaghari Anaraki S., Talebian A., Azarkeivan A. ,Maghsudlu M., Sarmadi M., Fatemi SH., Shahrabi A., Taherkhani Z

147. **Molecular blood genotyping in patients with Thalassemia major in Tehran Adult Thalassemic Clinic , Sci J Iran Blood Transfus Org 2009; 6(2):**

107-115 Shaiegan M., Samiee Sh., Azarkeivan A., Daneils J., Martin P.,Ataiee Z., Lotfi P., Kavari M., Lotfi H., Kasraiean L.,

148. **Anxiety and depration effects life and sleep quality in aduts withbeta thalassemia , Indian J Hematol Blood Transfus 25(2) 59-65** Bashir Hajibeigi, Azita Azarkeivan ,Seyed Moayad Alavian , Maryam Moghani Lankarani , Shervin Assari

149. **Molecular study of alpha-thalassemia mutations in Iranian potential carriers , Sci J Iran Blood Transfus Org 2010; 7(2): 70-77** Zarbakhsh B. , Farshadi E. , Ariani Kashani A. , Karimipoor M. , Azarkeivan A. ,Habibi Pourfatideh R., Fallah M.S., Maryami F., Kordafshari A.R.,Kaeini Moghadam Z., Bagherian H., Zeinali S.

150. **Evaluation of Coagulant inhibitors in patients with Thalassemia, Sci J Iran Blood Transfus Org 2010; 7(2): 78-84** Zahedpanah M., Azarkeivan .A., Hajibeigj B., Ahmady negad.M. , Eshghi P., Tabatabaie. M., Maghsoodlu,

151. **Trace back of thalassemic patients with positive HCV markers to their donors in Adult Thalassemia Center , Sci J Iran Blood Transfus Org 2010; 7(3): 156-161** Azarkeivan A., Hajibeigy B., Nasiritosi M., AminiKafiabad S., Maghsoodlu M., Shadman A . Afradi H.,Eslami M.S.

152. **Evaluation of clinical conditions of thalassemic patients having referred to Adult Thalassemia Center ,Sci J Iran Blood Transfus Org 2011; 8(1)** Azarkeivan A., Hajibeigy B.[1], Afradi H., Eslami, M.,Ghazizadeh Sh., Shabeh Pour Z.

153. **Evaluasion of the New Method of Washed RBCs (Closed system) in Comparison with the Old One(Open System) , The Journal of Zanjan Faculty of Medicine , 2011;19(75): 44 -**Azarkeivan A, Arjangyan MH, Hajibeigi B, Afradi H, Aghaeepour M, Razjoo F, Sharifi SH, Eshghi P

154. **Efficacy and safety of Iranian made Deferasirox (Osveral®)in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study , DARU Vol. 19, No. 3 2011 240-8** Eshghi P., Farahmandinia Z. , Molavi M., Naderi M. , Jafroodi M. , Hoorfar H., Davari K., Azarkeivan A., Keikhaie B. , Ansari S., Arasteh M.

155. **-Interferon alpha and pancytopenia in thalassemic patient who treating for HCV; Cause of death , Hepat Mon 2011; 11(1) 37-39** Bashir Hajibeigi,Azita Azarkeivan, Mohsen Nasiritosi

156. **Evaluation of new cases of HCV infection in thalassaemia patients for source of infection. Asian J Transfus Sci. 2011 Jul;5(2):132-5.** Azarkeivan A, Nasiritoosi M, Kafiabad SA, Maghsudlu M, Hajibeigi B, Hadizadeh M.

157. The modifying effect of Xmn1-HBG2 on thalassemic phenotype is associated with its linked elements in the beta globin locus control region, including the palindromic site at 5'HS4. Blood Cells Mol Dis. 2011 Oct 28. Neishabury M, Zamani S, Azarkeivan A, Abedini SS, Darvish H, Zamani F, Najmabadi H.

158. **Patient-to-Patient Transmission of Hepatitis C at Iranian Thalassemia Centers Shown by Genetic Characterization of Viral Strains. Hepat Mon. 2013 Jan 23;13(1)** Samimi-Rad K, Asgari F, Nasiritoosi M, Esteghamati A, Azarkeyvan A, Eslami SM, Zamani F, Magnius L, Alavian SM, Norder H.

159. Correlation between bone mineral densitometry and liver/heart iron overload evaluated by quantitative T2* MRI. Hematology. 2012 Sep;17(5):297-301. Ebrahimpour L, Akhlaghpoor S, Azarkayvan A, Salehi M, Morteza A, Alinaghi R.

160. Relation between serum ferritin and liver and heart MRI T2* in beta thalassaemia major patients, EMHJ • Vol. 19 No. 8 • 2013 ; 727-32 A. Azarkeivan, M. Hashemieh, S. Akhlaghpoor, A. Shirkavand, M. Yaseri and K. Sheibani .Eastern Mediterranean Health Journal .

161. Incidence of hepatocellular carcinoma in patients with thalassemia who had hepatitis C. Acta Med Iran. 2013 Jul 13;51(6):404-7. Ansari Sh , Azarkeivan A, Halagi F.

162. **Prevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran IJBC. 2014; 6 (3) :143-148** .Hashemieh M, Azarkeivan A, Radfar M, Saneifard H, Hosseini-Zijoud S, Noghabaei G, Yaseri M.

163. **Haemovigilance in Iran (First Report) . IJBC 2012;1: 7-11** :Faranoush M , Jalali F, Aminikafiabadi S , Balali MR , Azarkeivan A , Hajibeigi B, Paridar M , Asgharipoor 6, Zadsar M , Chegini A, Sharifi S, Manshadi M, Toogeh GR, Abolghassemi H

164. **Survival analysis of the thalassemia major patients using parametric and semiparametric survival models. Journal of Health**

Administration (JHA) 2015 Vol. 18 No. 59 pp. Pe82-Pe91 Khoei, R. A. A.; Bakhshi, E.; Azarkeivan, A.; Biglarian, A.

165. Knowledge, attitude, and preventive practice of major thalassemia patients regarding the importance of calcium and Vitamin D , Journal of Applied Hematology July 11, 2015, IP: 195.191.74.65] Bahare MehdiKhani , Ahmadreza Eslami , Mostafa Qorbani, Azita Azarkeivan , Zahra Mohammadi , Patricia Khashayar, Abbasali Keshtkar